Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Collaborative Health Research Projects (NSERC partnered)

McGill University

$277,440.00

Rapidly-Gelling, Guanosine 5' Diphosphate-Crosslinked Injectable Chitosan Sponges to Promote Oligodendrocyte Progenitor Cells' Differentiation Post-Spinal Cord Injuries

EF 2013-14

Résumé
In Canada, there are approximately 86,000 Canadians living with spinal cord injuries (SCI). The economic burden caused by SCI is immense, costing Canada an estimated $3.6 billion/Y. The initial trauma causes a contusion injury to the spinal cord resulting in damage to neurons and oligodendrocytes (OLGs). Secondary to trauma, there is additional neuronal and axonal loss, and damage to myelin and glia. The loss of myelin surrounding intact axons (demyelination) can result in functional loss because of the inability of these axons to effectively conduct nerve impulses. At present there are no effective treatments for SCI, and although many researchers are interested in neural regeneration, none are focused on developing biomaterials to target remyelination post-SCI. Therefore, the overall objective of this proposal is to use an injectable scaffold containing neurotrophic factors to promote the differentiation of endogenous OPCs and improve remyelination and neurological function post-SCI. We successfully developed a novel, rapidly-gelling, injectable chitosan sponge using Guanosine 5'-diphosphate (GDP). The sponges gel in less than 2 seconds, a highly desirable property to ensure localization at the site of injection. Moreover, the sponges were found to have very desirable physicochemical properties and excellent cytocompatibility. Brain Derived Neurotrophic Factor (BDNF) was successfully entrapped and released from the sponges in a controlled manner for up to 3 weeks. Furthermore, we demonstrated the successful attachment and differentiation of rat OPCs' on the chitosan sponges. Further studies are still required using rat OPCs to investigate myelination on the sponges. Furthermore, fetal and adult human OPCs' survival and differentiation on the sponges will be assessed. Finally, chitosan sponges will be injected in a contused mouse spinal cord model to study remyelination and recovery of neurological functions.
Programme
Collaborative Health Research Projects (NSERC partnered)
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
295771
Name
Tabrizian Maryam
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Natural Sciences and Engineering Research Council of Canada (NSERC)
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Collaborative Health Research Projects - NSERC Partnered
Projecttitle
Rapidly-Gelling, Guanosine 5' Diphosphate-Crosslinked Injectable Chitosan Sponges to Promote Oligodendrocyte Progenitor Cells' Differentiation Post-Spinal Cord Injuries
Programtype2
Operating Grants
Orgnameinp2
McGill University
Cihramount2
$277,440
Cihrequipment2
$0
Programname2
Collaborative Health Research Projects (NSERC partnered)
Keyworddelim
Bdnf/Igf-1 Or Nt-3 Delivery; Biomedical Engineering 1102; Biomedical Materials 1902; Biomedical Technology 1901; Chitosan Guanosine 5'-Diphosphate (Gdp)-Crosslinked Sponge; Contused Spinal Cord In A Mouse Model; Injectable Sponge; Life Sciences 1201; Rat & Human Oligodendrocyte Progenitor Cells Differentiation; Remyelination Post-Spinal Cord Injury
Abstract
In Canada, there are approximately 86,000 Canadians living with spinal cord injuries (SCI). The economic burden caused by SCI is immense, costing Canada an estimated $3.6 billion/Y. The initial trauma causes a contusion injury to the spinal cord resulting in damage to neurons and oligodendrocytes (OLGs). Secondary to trauma, there is additional neuronal and axonal loss, and damage to myelin and glia. The loss of myelin surrounding intact axons (demyelination) can result in functional loss because of the inability of these axons to effectively conduct nerve impulses. At present there are no effective treatments for SCI, and although many researchers are interested in neural regeneration, none are focused on developing biomaterials to target remyelination post-SCI. Therefore, the overall objective of this proposal is to use an injectable scaffold containing neurotrophic factors to promote the differentiation of endogenous OPCs and improve remyelination and neurological function post-SCI. We successfully developed a novel, rapidly-gelling, injectable chitosan sponge using Guanosine 5'-diphosphate (GDP). The sponges gel in less than 2 seconds, a highly desirable property to ensure localization at the site of injection. Moreover, the sponges were found to have very desirable physicochemical properties and excellent cytocompatibility. Brain Derived Neurotrophic Factor (BDNF) was successfully entrapped and released from the sponges in a controlled manner for up to 3 weeks. Furthermore, we demonstrated the successful attachment and differentiation of rat OPCs' on the chitosan sponges. Further studies are still required using rat OPCs to investigate myelination on the sponges. Furthermore, fetal and adult human OPCs' survival and differentiation on the sponges will be assessed. Finally, chitosan sponges will be injected in a contused mouse spinal cord model to study remyelination and recovery of neurological functions.
Competitiondate
201310
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Tabrizian, Maryam; Antel, Jack P
Approvedterm
3 ans 0 mois
Cihrcontribution2
Knowledge Translation Branch~ $277,440~ $0~